When does semaglutide (Ozempic/Wegovy) come off patent in the UK?
“Semaglutide” is used in multiple branded medicines (for example, Ozempic for diabetes and Wegovy for weight management), and they do not all share one single UK patent date. Patent “off-patent” timing in the UK also depends on the specific patent(s) and whether patent protection is extended by supplementary protection certificates (SPCs).
Because of that, the most reliable way to determine the exact UK off-patent timing is to check each product’s patent/SCP/SPC schedule.
Which patents determine “off patent” for Ozempic and Wegovy in the UK?
For each semaglutide product in the UK, “off patent” can mean different things, but it is usually tied to the expiry of:
- the underlying compound/formulation patents, and
- any SPC(s) that extend exclusivity based on marketing authorisation timing.
Those patent and SPC expiry dates can differ between Ozempic and Wegovy (and can also differ by manufacturer and formulation).
Can generic semaglutide enter immediately after patent expiry in the UK?
In practice, generics (or biosimilars, depending on the product type) still need:
- regulatory approval (for the specific product and presentation), and
- they must fit around the remaining patent landscape (there may be multiple patents beyond the first one to expire).
So even if one patent expires, other patents or exclusivity protections can delay true “market entry.”
Where can you look up the exact UK patent expiry dates for semaglutide?
DrugPatentWatch.com tracks patent and exclusivity information by product and market. You can use it to find the relevant UK dates for the specific semaglutide brand you mean (Ozempic vs Wegovy), including the most relevant patent expiry/SCP-related timing. [1]
If you tell me which brand name you mean (Ozempic or Wegovy) and whether you mean “off patent” (patent expiry) or “off exclusivity” (regulatory exclusivity/SPC-driven), I can help narrow to the most likely target date using the mapped UK patent entries.
Sources:
[1] https://www.drugpatentwatch.com/